Fk866
| Title | Journal |
|---|---|
| Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma. | Toxicology and applied pharmacology 20170915 |
| Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase. | Toxicological sciences : an official journal of the Society of Toxicology 20150301 |
| On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20140915 |
| Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. | Aging cell 20131201 |
| Visfatin is expressed in human granulosa cells: regulation by metformin through AMPK/SIRT1 pathways and its role in steroidogenesis. | Molecular human reproduction 20130501 |
| Nicotinamide phosphoribosyl transferase (Nampt) is a target of microRNA-26b in colorectal cancer cells. | PloS one 20130101 |
| Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. | EMBO molecular medicine 20121001 |
| Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells. | Biochemical and biophysical research communications 20120803 |
| Role of deleted in breast cancer 1 (DBC1) protein in SIRT1 deacetylase activation induced by protein kinase A and AMP-activated protein kinase. | The Journal of biological chemistry 20120706 |
| NAD+ levels control Ca2+ store replenishment and mitogen-induced increase of cytosolic Ca2+ by Cyclic ADP-ribose-dependent TRPM2 channel gating in human T lymphocytes. | The Journal of biological chemistry 20120615 |
| Inhibition of nicotinamide phosphoribosyltransferase modifies LPS-induced inflammatory responses of human monocytes. | Innate immunity 20120601 |
| Proinflammatory actions of visfatin/nicotinamide phosphoribosyltransferase (Nampt) involve regulation of insulin signaling pathway and Nampt enzymatic activity. | The Journal of biological chemistry 20120427 |
| NAMPT pathway is involved in the FOXO3a-mediated regulation of GADD45A expression. | Biochemical and biophysical research communications 20120420 |
| The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. | Haematologica 20120401 |
| Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase. | European journal of pharmacology 20120115 |
| Pre-B-cell colony-enhancing factor exerts a neuronal protection through its enzymatic activity and the reduction of mitochondrial dysfunction in in vitro ischemic models. | Journal of neurochemistry 20120101 |
| Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120101 |
| The NAMPT inhibitor FK866 reverts the damage in spinal cord injury. | Journal of neuroinflammation 20120101 |
| Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil. | Oncology reports 20111101 |
| Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells. | The Journal of pharmacology and experimental therapeutics 20110901 |
| Suppression of leukocyte infiltration and cartilage degradation by selective inhibition of pre-B cell colony-enhancing factor/visfatin/nicotinamide phosphoribosyltransferase: Apo866-mediated therapy in human fibroblasts and murine collagen-induced arthritis. | Arthritis and rheumatism 20110701 |
| Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents. | European journal of medicinal chemistry 20110401 |
| Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair. | Cancer research 20110315 |
| Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. | PloS one 20110101 |
| Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. | Experimental hematology 20101101 |
| Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. | The Journal of biological chemistry 20101029 |
| Nampt/PBEF/visfatin and cancer. | Cancer biology & therapy 20100715 |
| A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity. | Experimental biology and medicine (Maywood, N.J.) 20100701 |
| A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. | Molecular cancer therapeutics 20100601 |
| Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. | Cancer chemotherapy and pharmacology 20100501 |
| Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. | Proceedings of the National Academy of Sciences of the United States of America 20100202 |
| Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase. | BMC cancer 20100101 |
| Crystal structure of Rattus norvegicus Visfatin/PBEF/Nampt in complex with an FK866-based inhibitor. | Molecules and cells 20090630 |
| APO866 activity in hematologic malignancies: a preclinical in vitro study. | Blood 20090604 |
| Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. | Biochemical pharmacology 20090515 |
| Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. | Science (New York, N.Y.) 20090501 |
| Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. | Science (New York, N.Y.) 20090501 |
| Circadian rhythms. A circadian loop asSIRTs itself. | Science (New York, N.Y.) 20090501 |
| The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. | Blood 20090402 |
| Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. | PloS one 20090101 |
| Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. | The Journal of biological chemistry 20081212 |
| Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. | American journal of physiology. Renal physiology 20081101 |
| Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase. | Biochemistry 20081021 |
| Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage. | ChemMedChem 20080501 |
| NAD depletion by FK866 induces autophagy. | Autophagy 20080401 |
| Anticancer agent CHS-828 inhibits cellular synthesis of NAD. | Biochemical and biophysical research communications 20080321 |
| Characterization of NAD uptake in mammalian cells. | The Journal of biological chemistry 20080307 |
| The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. | Investigational new drugs 20080201 |
| Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. | Expert opinion on therapeutic targets 20070501 |
| Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866. | Journal of molecular biology 20060908 |
| Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. | European journal of medical research 20060830 |
| Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. | Nature structural & molecular biology 20060701 |
| Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050501 |
| FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. | Cancer research 20031101 |
| Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. | Anticancer research 20030101 |